How should borderline hypotension (systolic 90–100 mmHg) in a dialysis patient who cannot tolerate dialysis be managed?

Management of Borderline Hypotension in Dialysis Patients Unable to Tolerate Dialysis

Modify the dialysis prescription itself through a systematic approach: reduce dialysate temperature to 35°C, slow the ultrafiltration rate, increase dialysate sodium concentration to 145-148 mEq/L with sodium profiling, and consider administering midodrine 5-10 mg pre-dialysis to enable adequate dialysis delivery. 1

Algorithmic Approach to Management

Step 1: Reassess Target Dry Weight

• Do not assume hypotension equals correct dry weight 1
• Look for signs the target weight may be too low:
  • Improving nutritional markers (rising serum albumin, creatinine, or normalized protein catabolic rate)
  • Increased dietary intake
  • Hypotension occurring despite these improvements
• If present, increase the estimated dry weight incrementally

Step 2: Modify Ultrafiltration Strategy

Primary interventions:

• Extend dialysis treatment time to reduce hourly ultrafiltration rate (most critical intervention) 1
• Consider isolated ultrafiltration followed by diffusive clearance (sequential ultrafiltration/clearance) 1
  • This increases stroke index, cardiac index, and mean arterial pressure
  • Must extend total treatment time to compensate for time lost during isolated ultrafiltration
• Counsel on sodium and fluid restriction to minimize interdialytic weight gain 2

Step 3: Dialysate Modifications (Implement Simultaneously)

Temperature reduction (highly effective):

• Lower dialysate temperature from 37°C to 34-35°C 1
• Increases peripheral vasoconstriction and cardiac output
• Reduces intradialytic hypotension occurrence

Sodium profiling:

• Increase dialysate sodium to 145-148 mEq/L early in treatment 1
• Follow with continuous or stepwise decrease to 135-140 mEq/L by treatment end
• Caveat: May increase interdialytic weight gain and blood pressure between sessions 1

Buffer switch:

• Ensure bicarbonate-buffered dialysate (not acetate) 1
• Acetate inappropriately decreases vascular resistance and increases venous pooling

Step 4: Pharmacologic Intervention

Midodrine (first-line medication):

• Administer 5-10 mg (up to 25 mg) pre-dialysis 1, 3
• Selective alpha-1 adrenergic pressor agent
• Evidence shows significant increase in minimal systolic pressure from 93 to 107 mmHg during dialysis 3
• Contraindications: Avoid with other alpha-adrenergic agents (ephedrine, pseudoephedrine, phenylpropanolamine) due to supine hypertension risk 4
• Limited availability outside the United States 5

Alternative medications (weaker evidence):

• Sertraline for patients with paradoxical sympathetic withdrawal 4
• Intravenous L-carnitine 20 mg/kg with each session (reduces intradialytic hypotension frequency from 44% to 18%) 4
• Fludrocortisone, droxidopa (limited data) 5

Step 5: Correct Anemia

• Optimize hemoglobin to NKF-K/DOQI Anemia Guidelines range 1
• Anemia is a recognized risk factor for intradialytic hypotension 4

Step 6: Review Antihypertensive Medications

Critical timing consideration:

• Do not routinely withhold antihypertensives before dialysis - effectiveness unknown and under investigation 5
• Consider drug dialyzability patterns:
  • Nondialyzable agents (propranolol, carvedilol) may cause intradialytic hypotension 5
  • Highly dialyzable agents (atenolol, metoprolol, enalapril, ramipril) are removed during treatment 4, 5
• For frequent intradialytic hypotension: Avoid nondialyzable medications 5
• For stable intradialytic BP: Use once-daily, longer-acting agents for adherence 5

Critical Pitfalls to Avoid

1. Do not decrease blood flow and ultrafiltration rate reactively - this compromises dialysis adequacy and fails to meet ultrafiltration goals 1

2. Do not use hypotension as the sole indicator of volume status - it is unreliable for defining intravascular volume 1

3. Avoid excessive ultrafiltration - rates >6 mL/h/kg are associated with higher mortality and end-organ ischemia 5

4. Do not ignore the lag phenomenon - persistent hypertension between treatments should not be construed as failure of volume control 2

High-Risk Patient Identification

Patients most likely to experience intradialytic hypotension include those with 4:

• Diabetes mellitus with autonomic dysfunction
• Pre-dialysis systolic BP <100 mmHg
• Age ≥65 years
• Cardiovascular disease (LVH, diastolic dysfunction, CHF)
• Poor nutritional status/hypoalbuminemia
• Anephric status or prolonged dialysis duration

Combination Therapy for Resistant Cases

When single interventions fail, combine:

• Midodrine + cool dialysate (35°C) 4
• Cool dialysate + 3 mEq/L dialysate calcium 4
• Sodium profiling + temperature modeling 4

Alternative modalities (limited evidence):

• Hemofiltration or hemodiafiltration (improved plasma refill and hemodynamic stability) 4
• Extended daily dialysis or nocturnal hemodialysis (slower ultrafiltration rates) 4

Evidence Quality Note

The NKF-K/DOQI guidelines 1 provide the strongest framework, though they date from 2001. The 2020 KDIGO Controversies Conference 5 offers more recent guidance but acknowledges the evidence base remains relatively weak, with most medication studies being small and short-duration. The fundamental principle remains: modify the dialysis prescription itself rather than accepting inadequate dialysis delivery. 1